ConductScience.org, home

Paper42872124PubMed

Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy.

He M and 7 others. MedComm (2020), 2026.

Cite this record

ConductScience Library. Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy. Papers, record 42872124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy.
Journal
MedComm (2020)
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-15

Source PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1He MMinyihttps://orcid.org/0009-0004-8009-7371
2Yang HHuiting
3Shi YYunxing
4Zhang RRongqin
5Wan TTaixuan
6Pang XXiaolin
7Zhang ZZhanwen
8Huang LLiang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06608537A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134651226Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.Eur J Nucl Med Mol Imaging2022https://conductscience.org/library/papers/34651226PubMed
238572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
338462629Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.Signal Transduct Target Ther2024https://conductscience.org/library/papers/38462629PubMed
428939744Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Clin Cancer Res2017https://conductscience.org/library/papers/28939744PubMed
535133200MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy.Radiology2022https://conductscience.org/library/papers/35133200PubMed
639668486Dual-Time Point 68 Ga-FAPI-04 PET/CT Improves Tumor Delineation and Cervical Lymph Node Metastasis Identification in Patients With Head and Neck Squamous Cell Carcinoma.Clin Nucl Med2025https://conductscience.org/library/papers/39668486PubMed
739353648Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology.J Nucl Med2024https://conductscience.org/library/papers/39353648PubMed
827550820The biology and function of fibroblasts in cancer.Nat Rev Cancer2016https://conductscience.org/library/papers/27550820PubMed
93087717518F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.J Nucl Med2019https://conductscience.org/library/papers/30877175PubMed
1035063964Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.Clin Cancer Res2022https://conductscience.org/library/papers/35063964PubMed
1125483833The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.Radiother Oncol2014https://conductscience.org/library/papers/25483833PubMed
1233054291Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series.Rev Esp Enferm Dig2021https://conductscience.org/library/papers/33054291PubMed
1336813670FAPI-avid nonmalignant PET/CT findings: An expedited systematic review.Semin Nucl Med2023https://conductscience.org/library/papers/36813670PubMed
1436917951B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity.Cancer Cell2023https://conductscience.org/library/papers/36917951PubMed
1536387154Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer.Front Oncol2022https://conductscience.org/library/papers/36387154PubMed
168622014Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.J Clin Oncol1996https://conductscience.org/library/papers/8622014PubMed
1734725214Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.J Immunother Cancer2021https://conductscience.org/library/papers/34725214PubMed
1829626120A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.J Nucl Med2018https://conductscience.org/library/papers/29626120PubMed
1930544541TGFβ Superfamily Members as Regulators of B Cell Development and Function-Implications for Autoimmunity.Int J Mol Sci2018https://conductscience.org/library/papers/30544541PubMed
2033258746Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers.Radiology2021https://conductscience.org/library/papers/33258746PubMed

See all 44 referencesDownload CSV of references

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
FLUDEOXYGLUCOSE F 18CHEMBL2030434Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2030434

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42872124

GET https://conductscience.org/api/papers/v1/42872124/references?page=2